{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T08:06:27Z","timestamp":1789632387504,"version":"build-2803163510"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:00:00Z","timestamp":1777075200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:00:00Z","timestamp":1777075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"DOI":"10.1007\/s11255-026-05147-8","type":"journal-article","created":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T08:47:46Z","timestamp":1777106866000},"page":"4525-4533","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A high-sugar diet-induced animal model for insulin resistance, oxidative stress, and diabetic nephropathy: insights into empagliflozin\u2019s therapeutic potential"],"prefix":"10.1007","volume":"58","author":[{"given":"Ali","family":"Fardin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emad","family":"Gholami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina","family":"Maleki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Houman","family":"Parsaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1706-6212","authenticated-orcid":false,"given":"Habib","family":"Yaribeygi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,25]]},"reference":[{"issue":"1","key":"5147_CR1","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S2213-8587(13)70112-8","volume":"2","author":"PZ Zimmet","year":"2014","unstructured":"Zimmet PZ et al (2014) Diabetes: a 21st century challenge. Lancet Diabetes Endocrinol 2(1):56\u201364","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"5147_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.4103\/2468-8827.184853","volume":"1","author":"G Roglic","year":"2016","unstructured":"Roglic G (2016) WHO global report on diabetes: a summary. Int J Noncommun Dis 1(1):3\u20138","journal-title":"Int J Noncommun Dis"},{"issue":"3","key":"5147_CR3","doi-asserted-by":"publisher","first-page":"412","DOI":"10.3945\/an.116.014654","volume":"8","author":"RJ Johnson","year":"2017","unstructured":"Johnson RJ et al (2017) Perspective: a historical and scientific perspective of sugar and its relation with obesity and diabetes. Adv Nutr 8(3):412\u2013422","journal-title":"Adv Nutr"},{"issue":"6","key":"5147_CR4","doi-asserted-by":"publisher","first-page":"8152","DOI":"10.1002\/jcp.27603","volume":"234","author":"H Yaribeygi","year":"2019","unstructured":"Yaribeygi H et al (2019) Insulin resistance: review of the underlying molecular mechanisms. J Cell Physiol 234(6):8152\u20138161","journal-title":"J Cell Physiol"},{"issue":"Suppl 2","key":"5147_CR5","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s00394-016-1340-8","volume":"55","author":"IA MacDonald","year":"2016","unstructured":"MacDonald IA (2016) A review of recent evidence relating to sugars, insulin resistance and diabetes. Eur J Nutr 55(Suppl 2):17\u201323","journal-title":"Eur J Nutr"},{"issue":"12","key":"5147_CR6","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.3945\/jn.116.234047","volume":"146","author":"J Ma","year":"2016","unstructured":"Ma J et al (2016) Sugar-sweetened beverage but not diet soda consumption is positively associated with progression of insulin resistance and prediabetes. J Nutr 146(12):2544\u20132550","journal-title":"J Nutr"},{"issue":"33","key":"5147_CR7","doi-asserted-by":"publisher","first-page":"10194","DOI":"10.1021\/acs.jafc.2c03639","volume":"70","author":"S Chen","year":"2022","unstructured":"Chen S et al (2022) Alternative to sugar, honey does not provoke insulin resistance in rats based on lipid profiles, inflammation, and IRS\/PI3K\/AKT signaling pathways modulation. J Agric Food Chem 70(33):10194\u201310208","journal-title":"J Agric Food Chem"},{"key":"5147_CR8","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/B978-0-12-816918-6.00014-7","volume-title":"Dietary sugar, salt and fat in human health","author":"M Wojcik","year":"2020","unstructured":"Wojcik M et al (2020) Associations of high blood sugar with oxidative stress and inflammation in patients with type 2 diabetes. Dietary sugar, salt and fat in human health. Elsevier, pp 305\u2013323"},{"issue":"21","key":"5147_CR9","doi-asserted-by":"publisher","first-page":"11453","DOI":"10.3390\/ijms222111453","volume":"22","author":"E Gusev","year":"2021","unstructured":"Gusev E et al (2021) The pathogenesis of end-stage renal disease from the standpoint of the theory of general pathological processes of inflammation. Int J Mol Sci 22(21):11453","journal-title":"Int J Mol Sci"},{"issue":"4","key":"5147_CR10","doi-asserted-by":"publisher","first-page":"2990","DOI":"10.1002\/jcb.26450","volume":"119","author":"H Yaribeygi","year":"2018","unstructured":"Yaribeygi H et al (2018) Oxidative stress induces renal failure: a review of possible molecular pathways. J Cell Biochem 119(4):2990\u20132998","journal-title":"J Cell Biochem"},{"issue":"5","key":"5147_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/nu13051580","volume":"13","author":"LS Gewin","year":"2021","unstructured":"Gewin LS (2021) Sugar or fat? Renal tubular metabolism reviewed in health and disease. Nutrients 13(5):1580","journal-title":"Nutrients"},{"issue":"4","key":"5147_CR12","doi-asserted-by":"publisher","first-page":"F1256","DOI":"10.1152\/ajprenal.00181.2007","volume":"293","author":"MS Gersch","year":"2007","unstructured":"Gersch MS et al (2007) Fructose, but not dextrose, accelerates the progression of chronic kidney disease. Am J Physiol Renal Physiol 293(4):F1256\u2013F1261","journal-title":"Am J Physiol Renal Physiol"},{"key":"5147_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101751","author":"A Yang","year":"2023","unstructured":"Yang A et al (2023) Clinical outcomes following discontinuation of renin-angiotensin-system inhibitors in patients with type 2 diabetes and advanced chronic kidney disease: a prospective cohort study. EClinicalMedicine. https:\/\/doi.org\/10.1016\/j.eclinm.2022.101751","journal-title":"EClinicalMedicine"},{"issue":"6","key":"5147_CR14","first-page":"1","volume":"2","author":"M Rao","year":"2020","unstructured":"Rao M et al (2020) Sugar disease and its ramification on kidneys. J Clin Med Res 2(6):1\u201311","journal-title":"J Clin Med Res"},{"issue":"21","key":"5147_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11216544","volume":"11","author":"H Yaribeygi","year":"2022","unstructured":"Yaribeygi H et al (2022) Mechanistic view on the effects of SGLT2 inhibitors on lipid metabolism in diabetic milieu. J Clin Med 11(21):6544","journal-title":"J Clin Med"},{"issue":"11","key":"5147_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12113815","volume":"12","author":"H Yaribeygi","year":"2023","unstructured":"Yaribeygi H et al (2023) Sodium glucose cotransporter-2 inhibitor Empagliflozin increases antioxidative capacity and improves renal function in diabetic rats. J Clin Med 12(11):3815","journal-title":"J Clin Med"},{"issue":"2","key":"5147_CR17","first-page":"337","volume":"85","author":"CC Winterbourn","year":"1975","unstructured":"Winterbourn CC et al (1975) The estimation of red cell superoxide dismutase activity. J Lab Clin Med 85(2):337\u2013341","journal-title":"J Lab Clin Med"},{"key":"5147_CR18","first-page":"121","volume-title":"Methods in enzymology","author":"H Aebi","year":"1984","unstructured":"Aebi H (1984) [13] Catalase in vitro. Methods in enzymology. Elsevier, pp 121\u2013126"},{"issue":"3","key":"5147_CR19","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/0003-2697(69)90064-5","volume":"27","author":"F Tietze","year":"1969","unstructured":"Tietze F (1969) Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues. Anal Biochem 27(3):502\u2013522","journal-title":"Anal Biochem"},{"issue":"6","key":"5147_CR20","doi-asserted-by":"publisher","first-page":"F1144","DOI":"10.1152\/ajprenal.00221.2004","volume":"288","author":"M Satoh","year":"2005","unstructured":"Satoh M et al (2005) NAD (P) H oxidase and uncoupled nitric oxide synthase are major sources of glomerular superoxide in rats with experimental diabetic nephropathy. Am J Physiol Renal Physiol 288(6):F1144\u2013F1152","journal-title":"Am J Physiol Renal Physiol"},{"issue":"6","key":"5147_CR21","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1242\/dmm.007948","volume":"4","author":"L Palanker Musselman","year":"2011","unstructured":"Palanker Musselman L et al (2011) A high-sugar diet produces obesity and insulin resistance in wild-type Drosophila. Dis Model Mech 4(6):842\u2013849","journal-title":"Dis Model Mech"},{"issue":"3","key":"5147_CR22","doi-asserted-by":"publisher","first-page":"E258","DOI":"10.1152\/ajpendo.00267.2023","volume":"326","author":"LA Jahn","year":"2024","unstructured":"Jahn LA et al (2024) Empagliflozin improves vascular insulin sensitivity and muscle perfusion in persons with type 2 diabetes. Am J Physiol-Endocrinol Metab 326(3):E258\u2013E267","journal-title":"Am J Physiol-Endocrinol Metab"},{"key":"5147_CR23","doi-asserted-by":"publisher","DOI":"10.1080\/17446651.2025.2550733","author":"Y Pahlavan","year":"2025","unstructured":"Pahlavan Y et al (2025) Adding empagliflozin to ongoing metformin improves metabolic profile, tg-g and fib-4 indexes and liver function tests in type 2 diabetic patients with NAFLDS, a clinical trial. Expert Rev Endocrinol Metab. https:\/\/doi.org\/10.1080\/17446651.2025.2550733","journal-title":"Expert Rev Endocrinol Metab"},{"key":"5147_CR24","doi-asserted-by":"publisher","first-page":"1393946","DOI":"10.3389\/fphar.2024.1393946","volume":"15","author":"D Miklankova","year":"2024","unstructured":"Miklankova D et al (2024) Empagliflozin alters lipid metabolism in the myocardium and liver in a prediabetes model with severe dyslipidemia. Front Pharmacol 15:1393946","journal-title":"Front Pharmacol"},{"key":"5147_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1475-2840-13-28","volume":"13","author":"DZ Cherney","year":"2014","unstructured":"Cherney DZ et al (2014) The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovasc Diabetol 13:1\u20138","journal-title":"Cardiovasc Diabetol"},{"issue":"11","key":"5147_CR26","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/S2213-8587(19)30256-6","volume":"7","author":"BL Neuen","year":"2019","unstructured":"Neuen BL et al (2019) SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 7(11):845\u2013854","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"5147_CR27","doi-asserted-by":"publisher","first-page":"F194","DOI":"10.1152\/ajprenal.00520.2013","volume":"306","author":"V Vallon","year":"2014","unstructured":"Vallon V et al (2014) SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice. Am J Physiol Renal Physiol 306(2):F194\u2013F204","journal-title":"Am J Physiol Renal Physiol"},{"issue":"1","key":"5147_CR28","doi-asserted-by":"publisher","first-page":"S59","DOI":"10.1016\/j.amjcard.2017.05.012","volume":"120","author":"C Wanner","year":"2017","unstructured":"Wanner C (2017) EMPA-REG OUTCOME: the nephrologist\u2019s point of view. Am J Cardiol 120(1):S59\u2013S67","journal-title":"Am J Cardiol"},{"issue":"5","key":"5147_CR29","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1111\/dom.13648","volume":"21","author":"T Toyama","year":"2019","unstructured":"Toyama T et al (2019) Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and meta-analysis. Diabetes Obes Metab 21(5):1237\u20131250","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"5147_CR30","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1111\/dom.13301","volume":"20","author":"CC Dekkers","year":"2018","unstructured":"Dekkers CC et al (2018) Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers. Diabetes Obes Metab 20(8):1988\u20131993","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"5147_CR31","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s00125-016-4157-3","volume":"60","author":"V Vallon","year":"2017","unstructured":"Vallon V, Thomson SC (2017) Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. Diabetologia 60(2):215\u2013225","journal-title":"Diabetologia"},{"key":"5147_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115025","volume":"165","author":"W Guo","year":"2023","unstructured":"Guo W et al (2023) Renal intrinsic cells remodeling in diabetic kidney disease and the regulatory effects of SGLT2 Inhibitors. Biomed Pharmacother 165:115025","journal-title":"Biomed Pharmacother"},{"issue":"7","key":"5147_CR33","doi-asserted-by":"publisher","first-page":"sfae195","DOI":"10.1093\/ckj\/sfae195","volume":"17","author":"M Kanbay","year":"2024","unstructured":"Kanbay M et al (2024) Proximal tubule hypertrophy and hyperfunction: a novel pathophysiological feature in disease states. Clin Kidney J 17(7):sfae195","journal-title":"Clin Kidney J"},{"issue":"4","key":"5147_CR34","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1515920","volume":"375","author":"C Wanner","year":"2016","unstructured":"Wanner C et al (2016) Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375(4):323\u2013334","journal-title":"N Engl J Med"},{"issue":"1","key":"5147_CR35","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/jcp.26851","volume":"234","author":"H Yaribeygi","year":"2019","unstructured":"Yaribeygi H et al (2019) Sodium\u2013glucose cotransporter 2 inhibitors and inflammation in chronic kidney disease: possible molecular pathways. J Cell Physiol 234(1):223\u2013230","journal-title":"J Cell Physiol"},{"issue":"7","key":"5147_CR36","doi-asserted-by":"publisher","first-page":"674","DOI":"10.15537\/smj.2023.44.7.20230094","volume":"44","author":"AA Alshahrani","year":"2023","unstructured":"Alshahrani AA et al (2023) Metabolic and renal outcomes of empagliflozin in patients with type 2 diabetes mellitus attending Armed Forces Hospital in Saudi Arabia: retrospective cohort study. Saudi Med J 44(7):674","journal-title":"Saudi Med J"},{"issue":"2","key":"5147_CR37","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"Group, E.-K.C.","year":"2023","unstructured":"Group, E.-K.C. (2023) Empagliflozin in patients with chronic kidney disease. N Engl J Med 388(2):117\u2013127","journal-title":"N Engl J Med"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-026-05147-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-026-05147-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-026-05147-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T07:52:56Z","timestamp":1789631576000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-026-05147-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,25]]},"references-count":37,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["5147"],"URL":"https:\/\/doi.org\/10.1007\/s11255-026-05147-8","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,25]]},"assertion":[{"value":"30 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}